Cargando…

Is in-utero exposure to cannabis associated with the risk of attention deficit with or without hyperactivity disorder? A cohort study within the Quebec Pregnancy Cohort

IMPORTANCE AND OBJECTIVE: Prenatal cannabis effect on attention deficit with or without hyperactivity disorder (ADHD) remains to be determined. Our aim is to quantify the impact of in-utero exposure to cannabis on the risk of ADHD. DESIGN: Cohort study. SETTING: Questionnaires were mailed to women s...

Descripción completa

Detalles Bibliográficos
Autores principales: Tchuente, Vanina, Sheehy, Odile, Zhao, Jin-Ping, Gorgui, Jessica, Gomez, Yessica-Haydee, Berard, Anick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364390/
https://www.ncbi.nlm.nih.gov/pubmed/35940828
http://dx.doi.org/10.1136/bmjopen-2021-052220
_version_ 1784765136612884480
author Tchuente, Vanina
Sheehy, Odile
Zhao, Jin-Ping
Gorgui, Jessica
Gomez, Yessica-Haydee
Berard, Anick
author_facet Tchuente, Vanina
Sheehy, Odile
Zhao, Jin-Ping
Gorgui, Jessica
Gomez, Yessica-Haydee
Berard, Anick
author_sort Tchuente, Vanina
collection PubMed
description IMPORTANCE AND OBJECTIVE: Prenatal cannabis effect on attention deficit with or without hyperactivity disorder (ADHD) remains to be determined. Our aim is to quantify the impact of in-utero exposure to cannabis on the risk of ADHD. DESIGN: Cohort study. SETTING: Questionnaires were mailed to women sampled from the Quebec Pregnancy Cohort (QPC). Data from questionnaires were then linked with their QPC (built with administrative health databases, hospital patient charts and birth certificate databases). PARTICIPANTS: Respondents who gave birth to a singleton live born between January 1998 and December 2003 and were continuously enrolled in the Régie de l’assurance maladie du Québec (RAMQ) medication insurance plan for at least 12 months before the first day of gestation and during pregnancy. EXPOSURE: In-utero cannabis exposure was based on mothers’ answers to the question on cannabis use during pregnancy (yes/no) and categorised as occasionally, regularly exposed and unexposed if they chose one of these categories. OUTCOMES: ADHD was defined by a diagnosis of ADHD through the RAMQ medical services or MedEcho databases or a prescription filled for ADHD medication through RAMQ pharmaceutical services between birth and the end of the follow-up period. Follow-up started at the birth and ended at the index date (first diagnosis or prescription filled for ADHD), child death (censoring), end of public coverage for medications (censoring) or the end of study period, which was December 2015 (censoring), whichever event came first. RESULTS: A total of 2408 children met the inclusion criteria. Of these children, 86 (3.6%) were exposed to cannabis in-utero and 241 (10.0%) had an ADHD diagnosis or medication filled. After adjustments for potential confounders, no significant association was found between in-utero cannabis exposure (occasional (1.22 (95% CI 0.63 to 2.19)) or regular (1.22 (95% CI 0.42 to 2.79))) and the risk of ADHD in children. CONCLUSIONS: In-utero exposure to cannabis seemed to not be associated with the risk ADHD in children.
format Online
Article
Text
id pubmed-9364390
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-93643902022-08-22 Is in-utero exposure to cannabis associated with the risk of attention deficit with or without hyperactivity disorder? A cohort study within the Quebec Pregnancy Cohort Tchuente, Vanina Sheehy, Odile Zhao, Jin-Ping Gorgui, Jessica Gomez, Yessica-Haydee Berard, Anick BMJ Open Paediatrics IMPORTANCE AND OBJECTIVE: Prenatal cannabis effect on attention deficit with or without hyperactivity disorder (ADHD) remains to be determined. Our aim is to quantify the impact of in-utero exposure to cannabis on the risk of ADHD. DESIGN: Cohort study. SETTING: Questionnaires were mailed to women sampled from the Quebec Pregnancy Cohort (QPC). Data from questionnaires were then linked with their QPC (built with administrative health databases, hospital patient charts and birth certificate databases). PARTICIPANTS: Respondents who gave birth to a singleton live born between January 1998 and December 2003 and were continuously enrolled in the Régie de l’assurance maladie du Québec (RAMQ) medication insurance plan for at least 12 months before the first day of gestation and during pregnancy. EXPOSURE: In-utero cannabis exposure was based on mothers’ answers to the question on cannabis use during pregnancy (yes/no) and categorised as occasionally, regularly exposed and unexposed if they chose one of these categories. OUTCOMES: ADHD was defined by a diagnosis of ADHD through the RAMQ medical services or MedEcho databases or a prescription filled for ADHD medication through RAMQ pharmaceutical services between birth and the end of the follow-up period. Follow-up started at the birth and ended at the index date (first diagnosis or prescription filled for ADHD), child death (censoring), end of public coverage for medications (censoring) or the end of study period, which was December 2015 (censoring), whichever event came first. RESULTS: A total of 2408 children met the inclusion criteria. Of these children, 86 (3.6%) were exposed to cannabis in-utero and 241 (10.0%) had an ADHD diagnosis or medication filled. After adjustments for potential confounders, no significant association was found between in-utero cannabis exposure (occasional (1.22 (95% CI 0.63 to 2.19)) or regular (1.22 (95% CI 0.42 to 2.79))) and the risk of ADHD in children. CONCLUSIONS: In-utero exposure to cannabis seemed to not be associated with the risk ADHD in children. BMJ Publishing Group 2022-08-08 /pmc/articles/PMC9364390/ /pubmed/35940828 http://dx.doi.org/10.1136/bmjopen-2021-052220 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Paediatrics
Tchuente, Vanina
Sheehy, Odile
Zhao, Jin-Ping
Gorgui, Jessica
Gomez, Yessica-Haydee
Berard, Anick
Is in-utero exposure to cannabis associated with the risk of attention deficit with or without hyperactivity disorder? A cohort study within the Quebec Pregnancy Cohort
title Is in-utero exposure to cannabis associated with the risk of attention deficit with or without hyperactivity disorder? A cohort study within the Quebec Pregnancy Cohort
title_full Is in-utero exposure to cannabis associated with the risk of attention deficit with or without hyperactivity disorder? A cohort study within the Quebec Pregnancy Cohort
title_fullStr Is in-utero exposure to cannabis associated with the risk of attention deficit with or without hyperactivity disorder? A cohort study within the Quebec Pregnancy Cohort
title_full_unstemmed Is in-utero exposure to cannabis associated with the risk of attention deficit with or without hyperactivity disorder? A cohort study within the Quebec Pregnancy Cohort
title_short Is in-utero exposure to cannabis associated with the risk of attention deficit with or without hyperactivity disorder? A cohort study within the Quebec Pregnancy Cohort
title_sort is in-utero exposure to cannabis associated with the risk of attention deficit with or without hyperactivity disorder? a cohort study within the quebec pregnancy cohort
topic Paediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364390/
https://www.ncbi.nlm.nih.gov/pubmed/35940828
http://dx.doi.org/10.1136/bmjopen-2021-052220
work_keys_str_mv AT tchuentevanina isinuteroexposuretocannabisassociatedwiththeriskofattentiondeficitwithorwithouthyperactivitydisorderacohortstudywithinthequebecpregnancycohort
AT sheehyodile isinuteroexposuretocannabisassociatedwiththeriskofattentiondeficitwithorwithouthyperactivitydisorderacohortstudywithinthequebecpregnancycohort
AT zhaojinping isinuteroexposuretocannabisassociatedwiththeriskofattentiondeficitwithorwithouthyperactivitydisorderacohortstudywithinthequebecpregnancycohort
AT gorguijessica isinuteroexposuretocannabisassociatedwiththeriskofattentiondeficitwithorwithouthyperactivitydisorderacohortstudywithinthequebecpregnancycohort
AT gomezyessicahaydee isinuteroexposuretocannabisassociatedwiththeriskofattentiondeficitwithorwithouthyperactivitydisorderacohortstudywithinthequebecpregnancycohort
AT berardanick isinuteroexposuretocannabisassociatedwiththeriskofattentiondeficitwithorwithouthyperactivitydisorderacohortstudywithinthequebecpregnancycohort